The immunogenic and protective properties of inactivated and live candidate vaccines against highly pathogenic avian influenza H5N1 virus


Cite item

Full Text

Abstract

The present study in BALB/c mice was conducted to compare immunogenicity and protective efficacy of several candidate vaccines based on homologous and heterologous strains after challenge with the highly pathogenic avian influenza strain A/Chicken/Kurgan/3/2005.
The experimental vaccine composed of an inactivated split A/Vietnam/1194/2004 (H5N1) strain and a plant derived adjuvant has demonstrated better immunogenic properties versus the variant of the vaccine with aluminum hydroxide. Interestingly, the heterosubtypic H1N1 live attenuated vaccine candidate administered intranasally protected 93% of the subject against their challenge with HPIV H5N1.

References

  1. Каплун А. П., Илларионов В. В., Балакшин В. В. и др. Носитель лекарственных и диагностических средств. Пат. РФ № 2322998 С1. Опубл. 27.04.08; Бюл. № 12.
  2. Найхин А. Н., Рекстин А. Р., Баранцева И. Б. и др. Иммунный ответ на живую гриппозную вакцину // Вестн. РАМН. - 2002. - № 12. - С. 24-28.
  3. Desheva J. A., Lu X. H., Rekstin A. R. et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential // Vaccine. - 2006. - Vol. 24, N 47-48. - P. 6859-6866.
  4. Kreijtz J. H., Bodewes R., van Amerongen G. et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice // Vaccine. - 2007. - Vol. 25, N 4. - P. 612-620.
  5. Lu X., Edwards L. E., Desheva J. A. et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses // Vaccine. - 2006. - Vol. 24, N 44-46. - P. 6588-6593.
  6. Nicholson K. G., Colegate A. E., Podda A. et al. Safety and antigenicity of non-adjuvated and MF59-adjuvated influenza A/ Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza // Lancet. - 2001. - Vol. 357. - P. 1937-1943.
  7. Ovcharenko A. V., Zhirnov O. P. Aprotinin aerosol treatment of influenza and para-myxovirus bronchopneumonia of mice // Antiviral Res. - 1994. - Vol. 23. - P. 107-118.
  8. Stephenson I., Nicholson K. G., Colegate A. et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/ Duck/Singapore/97 vaccine in a primed human population // Vaccine. - 2003. - Vol. 21. - P. 1687-1693.
  9. Stephenson I., Bugarini R., Nicholson K. G. et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/ Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy // J. Infect. Dis. - 2005. - Vol. 191. - P. 1210-1215.
  10. Suguitan A. L. Jr., McAuliffe J., Mills K. L. et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets // PLoS Med. - 2006. - Vol. 3, N 9. - P. 1541-1554.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Krasil'nikov I.V., Gambaryan A.S., Mashin V.V., Lobastova A.K., Krasilnikov I.V., Gambaryan A.S., Mashin V.V., Lobastova A.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies